DUBLIN - November 30, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the availability of a new CareLink® iPro report called Pattern Snapshot for iPro2 Professional CGM system. The new one-page report provides a health care professional (HCP) with information for quick interpretation of detailed glucose data over time. The identified patterns are based on advanced algorithms that automatically identify an individual's top glucose control issues and their possible causes. The report information and visuals also serve as a teaching tool to help educate people with diabetes about their own glucose profile.

The iPro2 system provides physicians with insights into how their patients' diet, medication, and daily activities affect glucose levels. Much like a holter monitor for cardiovascular care, the iPro2 Professional CGM device records a patient's glucose levels 24 hours a day for up to three days and provides user-friendly reports to the physician. The physicians accordingly use these simple reports to make therapy adjustments, recommendations and educational decisions for their patients.

 "We developed this rule-based, simplified report to enhance the use of professional CGM as part of the overall diabetes management regimen," stated Laura Stoltenberg, general manager of Medtronic's Non-Intensive Diabetes Therapies business unit. "HCPs will now have a simplified report that will allow for faster interpretation of the most important diabetes metrics, so they can quickly uncover their patient's most important issues."

Pattern Snapshot identifies the top three issues in a patient's glucose profile, providing details of each priority issue. This includes possible causes for each pattern, as well as visuals of meal times and daily glucose values, thereby allowing physicians to uncover more information in less time.

"The retrospective CGM technology of Medtronic's iPro2 Professional CGM presents the patient and provider with accurate information that allows personalized treatment decisions.  This comprehensive yet easy-to-interpret continuous glycemic data will arm the care team with valuable and previously difficult to obtain data," said Todd M. Zeiger, M.D., vice president, UH Primary Care Institute, Cleveland, OH.

The use of professional CGM is on the rise in the U.S. Several published studies have shown the benefits of professional CGM in modifying treatment, capturing more episodes of low blood sugar, which can be a serious condition if left untreated, and as an educational tool for improved glycemic control.i, ii, iii

To learn more about the iPro2 Professional CGM system visit: http://professional.medtronicdiabetes.com/ipro2-professional-cgm  

About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:
Amanda Sheldon
Public Relations
+1-818-576-4826

Ryan Weispfenning
Investor Relations
+1-763-505-4626